Stanford MS&E435 Economics of the AI Supercycle | Spring 2026 | Applications, AI in Life Sciences

Artificial intelligence is transforming the pharmaceutical industry by transitioning drug discovery from an experimental, trial-and-error process into an engineering discipline, with the potential to reduce development timelines from over a decade to a few years.

• Development timeline — Conventional processes span 10 to 15 years; AI integration aims to reduce this significantly by streamlining target selection and preclinical phases [10:56].

• Engineering approach — Developers treat molecules as software, creating computer-aided design (CAD) suites to generate therapeutic candidates directly in silicon [03:06].

• Outer loop acceleration — Foundation models act as agents that manage the iterative process of design, testing, and debugging, which previously required months of manual lab work [22:47].

• Competitive pressure — Global geopolitical factors, particularly the rapid drug discovery advancements in China, are accelerating the adoption of AI-native methodologies in Western pharmaceutical companies [21:04].

• Data scaling — Advancements in high-throughput measurement techniques, including proteomics and single-cell sequencing, provide the necessary volume to train models that exceed human expert performance [23:36].

• Target expansion — The industry historically focuses on roughly 30 targets annually; AI platforms are designed to evaluate thousands of potential genomic targets simultaneously [12:35].

• Wet lab integration — Firms are establishing physical laboratories to act as validation sandboxes for AI models, allowing direct feedback between digital designs and biological reality [26:41].

• What are the primary challenges in integrating AI models with physical lab instrumentation?

• How do current AI platforms manage the validation of drug candidates that require complex multi-step synthesis?